Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1970 1
1972 7
1973 9
1974 10
1975 13
1976 18
1977 21
1978 25
1979 15
1980 19
1981 26
1982 29
1983 20
1984 23
1985 26
1986 33
1987 16
1988 23
1989 22
1990 22
1991 13
1992 17
1993 13
1994 19
1995 12
1996 22
1997 19
1998 20
1999 17
2000 18
2001 31
2002 21
2003 33
2004 37
2005 44
2006 43
2007 55
2008 38
2009 57
2010 76
2011 87
2012 107
2013 123
2014 133
2015 139
2016 156
2017 157
2018 127
2019 139
2020 135
2021 167
2022 102
2023 117
2024 171
2025 225
2026 30

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,830 results

Results by year

Filters applied: . Clear all
Page 1
Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.
Akar S, Duran T, Azzawri AA, Koçak N, Çelik Ç, Yıldırım Hİ. Akar S, et al. J Obstet Gynaecol. 2021 Nov;41(8):1240-1245. doi: 10.1080/01443615.2020.1854696. Epub 2021 Mar 1. J Obstet Gynaecol. 2021. PMID: 33645410
The anti-proliferative effects of 5-methylquinolinium (5MQ) of nicotinamide N-methyltransferase (NNMT) have not been previously investigated on a cervical cancer cell line. NNMT is a metabolic enzyme that is correlated with tumour progression and metastasis. 5MQ is …
The anti-proliferative effects of 5-methylquinolinium (5MQ) of nicotinamide N-methyltransferase (NNMT) have not been previousl …
Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase.
Ruf S, Hallur MS, Anchan NK, Swamy IN, Murugesan KR, Sarkar S, Narasimhulu LK, Putta VPRK, Shaik S, Chandrasekar DV, Mane VS, Kadnur SV, Suresh J, Bhamidipati RK, Singh M, Burri RR, Kristam R, Schreuder H, Czech J, Rudolph C, Marker A, Langer T, Mullangi R, Yura T, Gosu R, Kannt A, Dhakshinamoorthy S, Rajagopal S. Ruf S, et al. Bioorg Med Chem Lett. 2018 Mar 1;28(5):922-925. doi: 10.1016/j.bmcl.2018.01.058. Epub 2018 Jan 31. Bioorg Med Chem Lett. 2018. PMID: 29433927
Nicotinamide N-methyltransferase (NNMT) has been linked to obesity and diabetes. We have identified a novel nicotinamide (NA) analog, compound 12 that inhibited NNMT enzymatic activity and reduced the formation of 1-methyl-nicotinamide (MNA), the primary metabolite …
Nicotinamide N-methyltransferase (NNMT) has been linked to obesity and diabetes. We have identified a novel nicotinamide (NA) …
Revumenib: First Approval.
Syed YY. Syed YY. Drugs. 2025 Apr;85(4):577-583. doi: 10.1007/s40265-025-02161-5. Drugs. 2025. PMID: 40072775 Review.
Revumenib (Revuforj()) is an oral, first-in-class menin inhibitor developed by Syndax Pharmaceuticals for the treatment of KMT2A-rearranged (KMT2Ar) acute leukaemia, NPM1-mutated (NPM1m) acute myeloid leukaemia (AML) and solid tumours. ...
Revumenib (Revuforj()) is an oral, first-in-class menin inhibitor developed by Syndax Pharmaceuticals for the treatment of KMT2A-rear …
Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model.
Li S, Rodrigues PG, Chakraborty AD, Correia C, Schouten EM, Strömstedt M, Löfgren L, Persson M, Fredlund L, Rohman M, Bergström F, Akerud T, Ericson C, Kreisel K, Guzman MM, Silljé HHW, de Boer RA, Meems LMG. Li S, et al. Pharmacol Res. 2025 Jul;217:107820. doi: 10.1016/j.phrs.2025.107820. Epub 2025 Jun 6. Pharmacol Res. 2025. PMID: 40484359 Free article.
A potential treatment option may be Nicotinamide N-methyltransferase (NNMT) inhibition. This study aimed to investigate the cardiac protective effects of the NNMT enzyme inhibitor AMO-NAM in a HFpEF mouse model. Aged (18-22 months old) female mice developed a …
A potential treatment option may be Nicotinamide N-methyltransferase (NNMT) inhibition. This study aimed to investigate the ca …
Esterase-Sensitive Prodrugs of a Potent Bisubstrate Inhibitor of Nicotinamide N-Methyltransferase (NNMT) Display Cellular Activity.
van Haren MJ, Gao Y, Buijs N, Campagna R, Sartini D, Emanuelli M, Mateuszuk L, Kij A, Chlopicki S, Escudé Martinez de Castilla P, Schiffelers R, Martin NI. van Haren MJ, et al. Biomolecules. 2021 Sep 14;11(9):1357. doi: 10.3390/biom11091357. Biomolecules. 2021. PMID: 34572571 Free PMC article.
A recently discovered bisubstrate inhibitor of Nicotinamide N-methyltransferase (NNMT) was found to be highly potent in biochemical assays with a single digit nanomolar IC(50) value but lacking in cellular activity. We, here, report a prodrug strategy designe …
A recently discovered bisubstrate inhibitor of Nicotinamide N-methyltransferase (NNMT) was found to be highly potent in …
Transition-State Analogues of Phenylethanolamine N-Methyltransferase.
Mahmoodi N, Harijan RK, Schramm VL. Mahmoodi N, et al. J Am Chem Soc. 2020 Aug 19;142(33):14222-14233. doi: 10.1021/jacs.0c05446. Epub 2020 Aug 7. J Am Chem Soc. 2020. PMID: 32702980 Free PMC article.
Phenylethanolamine N-methyltransferase (PNMT) is a critical enzyme in catecholamine synthesis. It transfers the methyl group of S-adenosylmethionine (SAM) to catalyze the synthesis of epinephrine from norepinephrine. ...Synthetic efforts resulted in a tight-binding …
Phenylethanolamine N-methyltransferase (PNMT) is a critical enzyme in catecholamine synthesis. It transfers the methyl group o …
Nicotinamide n-methyltransferase inhibitor synergizes with sodium-glucose cotransporter 2 inhibitor to protect renal tubular epithelium in experimental models of type 2 diabetes mellitus.
Yang Y, Li F, Li Y, Li X, Zhao Z, Zhang N, Li H. Yang Y, et al. J Diabetes Complications. 2025 Feb;39(2):108952. doi: 10.1016/j.jdiacomp.2025.108952. Epub 2025 Jan 18. J Diabetes Complications. 2025. PMID: 39848127
AIMS: We aim to explore the potential of nicotinamide n-methyltransferase (NNMT) as a sensitive marker of renal tubular injury and the possibility of an NNMT inhibitor to combine with sodium-glucose cotransporter 2 (SGLT2) inhibitor to protect proximal …
AIMS: We aim to explore the potential of nicotinamide n-methyltransferase (NNMT) as a sensitive marker of renal tubular injury …
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction.
Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Babula JJ, et al. Diabetes Obes Metab. 2024 Nov;26(11):5272-5282. doi: 10.1111/dom.15879. Epub 2024 Aug 19. Diabetes Obes Metab. 2024. PMID: 39161060 Free PMC article.
AIM: To assess the effects of a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor, 5A1MQ, on body composition, metabolic variables, fatty liver pathologies, and circulating biomarkers in diet-induced obese (DIO) mice, and characterize its plasm …
AIM: To assess the effects of a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor, 5A1MQ, on body compos …
Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges.
Gold S, Shilatifard A. Gold S, et al. J Clin Invest. 2024 Oct 15;134(20):e183391. doi: 10.1172/JCI183391. J Clin Invest. 2024. PMID: 39403928 Free PMC article. Review.
Clinically viable therapies targeting the activities of histone lysine methyltransferases (HKMT) and demethylases (HKDMs) have only recently begun to emerge following FDA approval of the EZH2 inhibitor tazemetostat in 2020 and remain limited to compounds targeting the well …
Clinically viable therapies targeting the activities of histone lysine methyltransferases (HKMT) and demethylases (HKDMs) have only recently …
Nicotinamide N-methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions.
Liu A, Zhu XJ, Sun WD, Bi SZ, Zhang CY, Lai SY, Li JH. Liu A, et al. Exp Neurol. 2025 Jul;389:115253. doi: 10.1016/j.expneurol.2025.115253. Epub 2025 Apr 10. Exp Neurol. 2025. PMID: 40221009 Review.
Emerging evidence highlights nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme regulating nicotinamide (NAM) methylation, as a pivotal player in NDs through its dual impact on epigenetic regulation and metabolic homeostasis. ...Therapeutic strategies targe …
Emerging evidence highlights nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme regulating nicotinamide (NAM) methyla …
2,830 results